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Five cases of non-small cell lung cancer, associated withgermline transmission of epidermal growth factor receptor
(EGFR)-T790M mutation, have been reported1; these patients
had family histories of lung cancer. The activity of gefitinib
was tested in only two patients, who were both refractory to
this drug.2 Herein, we describe a family of European descent
in which two family members had non-small cell lung cancer
associated with germline transmission of T790M mutation
and who were treated with gefitinib (Figure 1A).
The proband was a 72-year-old female, never-smoker,
who was diagnosed with an adenocarcinoma of the lung with
bilateral pulmonary lesions. This patient was initially treated
with chemotherapy for four courses, resulting in stable disease
for 6 months, as determined by radiological examination. When
the disease progressed, treatment with oral gefitinib at the dose
of 250 mg/d was initiated, resulting in a partial response lasting
for 9 months; subsequently, the patient developed pleural and
cerebral progression of disease and died within 5 months.
A 74-year-old never-smoker sister of the proband was
diagnosed with a poor differentiated locally advanced (stage
IIIB for pleural effusion) carcinoma of the lung and was treated
with a first-line chemotherapy, resulting in a partial response
lasting for 12 months, after which new bone metastases were
observed. As second-line treatment, oral gefitinib 250 mg/d
was started, and a partial response was obtained that is lasting
from 45 months; the patient is still alive and on treatment
with gefitinib. No other members of this family developed
lung cancer.
DNA was isolated from peripheral blood mononu-
clear cells or paraffin-embedded tumor samples, using the
microDNA-kit (Qiagen, Hilden, Germany). Nested polymer-
ase chain reaction to amplify EGFR (exons 18–21) and
K-RAS (exon 1) and sequencing of polymerase chain reaction
products on a ABI-3100 Genetic Analyzer was performed.
The EGFR-T790M mutation was found in the germline
DNA of both patients (Figure 1B), whereas no mutations
were detected in the EGFR exons 18, 19, and 21. In contrast,
no EGFR mutations were observed in the two daughters of
proband and in the two sons of individual II.
In the tumor tissue of individual I, we identified the
deletion of EGFR E746-A750 in exon 19 but no EGFR
mutations in the exons 18, 20, and 21 (Figure 1C). In the
tissue of individual II, no EGFR mutations in the exons 18,
19, and 21 were found, whereas the exon 20 could not be
studied because no sufficient tumor tissue was present. No
mutations were observed in codons 12 and 13 of K-RAS exon
1 in the tissues of both patients.
Our data support the hypothesis that an inherited
T790M mutation confers an enhanced susceptibility to de-
velop lung tumors3; moreover, the presence of a T790M
germline mutation does not necessarily predict for resistance
to EGFR-tyrosine kinase inhibitors.
The responses to gefitinib could possibly be due to the
absence of T790M and K-RAS mutations and the occurrence of
EGFR-activating mutations in the tumor tissues. However, other
mechanisms, such as increased gene copy number,4 may be
responsible for response to gefitinib in the case of individual II.
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FIGURE 1. A, Pedigree of a family with cases of non-small cell lung cancers. B, Representative electropherogram for EGFR
sequencing of the samples of the proband (sample #1) and her sister (sample #2). Sample #1 and #2 harbored a T790M mu-
tation that was read from both the forward and reverse sequence. The figure also includes a positive control. Furthermore, the
analysis included a sample with a known wild-type sequence at position 790, and a negative control (water), which was nega-
tive, excluding the chance of contamination. C, Representative electropherogram of the deletion E746-A750 (ELREA) in EGFR
exon 19 (panel B) in comparison with the wild-type sequence (panel A), as detected in the tumor tissue of the proband.
EGFR, epidermal growth factor receptor.
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